Newsletter

Stay up to date on all things atrial fibrillation. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter

January 24, 2020

Overview

The goal of this study is to compare heart rate control (heart rate <110 beats per minute) at 2 hours after taking the medication diltiazem orally vs. intravenously. Diltiazem is a non-dihydropyridine calcium channel blocker medication used to manage atrial fibrillation. Patients will receive either an oral dose or intravenous dose of diltiazem and their heart rates will be monitored. Incidence of adverse events will be logged as well (heart rate <60 beats per minute, systolic blood pressure <90 mmHg requiring intervention).

 

Study Information

320 subjects will be enrolled in the study. The primary purpose of the trial is treatment. The study began on June 1, 2018 and is estimated to be completed by March 2021.

 

Inclusion Criteria

 

  • >/= 18 years old
  • Atrial fibrillation or flutter on electrocardiogram
  • Heart rate >110 beats/min
  • Systolic blood pressure >/= 90 mmHg

 

Exclusion Criteria

 

  • Limited English proficiency (LEP)
  • Pregnant
  • Prisoners
  • Wolff Parkinson White syndrome
  • Administration of electrical or chemical cardioversion before screening
  • Administration of other antiarrhythmics for acute heart rate control (excluding adenosine)
  • History of allergy or idiosyncratic reaction to diltiazem
  • Unable to take oral medications
  • Heart rate <60 beats/min

 

Location

The study will take place at Virginia Commonwealth University, Richmond, Virginia, United States, 23298. If you have any questions, please contact Tammy T Nguyen, PharmD, BCPS at 804-663-0969 / tammy.nguyen@vcuhealth.org.

 

Sponsors / Collaborators

This study is sponsored by Virginia Commonwealth University. The principal investigator is Tammy T Nguyen, PharmD, BCPS of Virginia Commonwealth University.

View All Clinical Trials

Clinical Trials

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

This study aims to survey patients with atrial fibrillation in order to understand direct-acting oral anticoagulant (DOAC) treatment from the…

iCLAS for Persistent Atrial Fibrillation

This study aims to evaluate the safety of the Adagio AF Cryoablation System (iCLAS™) for ablation treatment of persistent atrial fibrillation.…

Esophageal Deviation in Atrial Fibrillation Ablation

Ablation treatment in the posterior wall of the left atrium can cause thermal injury to the esophagus, which is a very common occurrence. The goal…

Low Voltage-Directed Catheter Ablation for Atrial Fibrillation

The goal of this study is to determine the long term success of non-paroxysmal ablation to treat atrial fibrillation using three different…

The Genetic Basis for Atrial Fibrillation

Veteran patients with atrial fibrillation will be examined for common genetic polymorphisms, and identify…

Liraglutide Effect in Atrial Fibrillation

The goal of this study is to use a medication called Liraglutide to reduce fat deposits surrounding the heart, and…

Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation

The goal of this study is to see how electrogram morphology recurrence (EMR) mapping works on patients with atrial…

High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation

The goal of the study is to find a correlation between FIRM targeted sites and micro-anatomic fibrotic tracks. Patients will first undergo a…

Send this to a friend